Related Experiment Video
Updated: Mar 29, 2026
11:10
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
2.8K
IFN-γ for Friedreich ataxia: present evidence
McKenzie Wells1,2, Lauren Seyer1,2, Kimberly Schadt1,2
1Departments of Pediatrics & Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Neurodegenerative Disease Management
|December 5, 2015
Summary
Interferon gamma-1b (IFN-γ-1b) showed good tolerability and improved neurological function in a Phase I trial for Friedreich
Area of Science:
- Neuroscience
- Immunology
- Rare Diseases
Background:
- Interferon gamma-1b (IFN-γ-1b) is an FDA-approved orphan drug for specific conditions.
- IFN-γ-1b is being investigated as a potential therapy for Friedreich ataxia (FRDA).
Purpose of the Study:
- To evaluate the safety and efficacy of IFN-γ-1b in pediatric patients with FRDA.
Main Methods:
- A Phase I, open-label trial was conducted in children with FRDA.
- Neurological function was assessed using the Friedreich Ataxia Rating Scale (FARS).
- Frataxin levels were monitored as a primary outcome measure.
Main Results:
- IFN-γ-1b was reasonably well-tolerated in the pediatric FRDA population.
- A 12-week treatment course showed improvement in overall neurological function based on FARS scores.
- No significant improvement in frataxin levels was observed.
Conclusions:
- IFN-γ-1b demonstrates acceptable tolerability and potential for improving neurological function in FRDA.
- Further investigation in Phase II and III trials is warranted to confirm efficacy and optimal dosing for FRDA.
- The current study highlights the need for continued research into IFN-γ-1b for rare neurological disorders.
